We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19.

Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system. Our approach to cancer therapy is based on the belief that patients will require a multimodal, multipronged approach – targeting a single or diverse set of cellular targets and attacking those on several fronts – simultaneously or sequentially, frequently and relentlessly.

Our approach to fighting cancer is made possible by a unique immuno-oncology (“I-O”) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (“G-MAB™”) that can be used on their own or incorporated into cancer-targeting approaches.